Coherus Oncology, Inc.
CHRS$82M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaREDWOOD CITY158 employees
Drugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
17dMarket Overview
Stock performance and key metrics
CHRS News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Etanercept
Rheumatoid Arthritis
CHS-0214
Plaque Psoriasis
CHS-1420
Plaque Psoriasis
Casdozokitug
Hepatocellular Carcinoma
SRF388
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
CHS-0214 | Phase 3 | Plaque Psoriasis | - | - |
CHS-1420 | Phase 3 | Plaque Psoriasis | - | - |
Casdozokitug | Phase 2 | Hepatocellular Carcinoma | - | - |
SRF388 | Phase 2 | Hepatocellular Carcinoma | - | - |
Hepatocellular Carcinoma
2 drugs in this indication
Plaque Psoriasis
2 drugs in this indication
Rheumatoid Arthritis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply